These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Minimal residual disease quantification in childhood acute lymphoblastic leukemia by real-time polymerase chain reaction using the SYBR green dye. Li AH; Forestier E; Rosenquist R; Roos G Exp Hematol; 2002 Oct; 30(10):1170-7. PubMed ID: 12384148 [TBL] [Abstract][Full Text] [Related]
3. Minimal residual disease detection by mutation-specific droplet digital PCR for leukemia/lymphoma. Shirai R; Osumi T; Keino D; Nakabayashi K; Uchiyama T; Sekiguchi M; Hiwatari M; Yoshida M; Yoshida K; Yamada Y; Tomizawa D; Takae S; Kiyokawa N; Matsumoto K; Yoshioka T; Hata K; Hori T; Suzuki N; Kato M Int J Hematol; 2023 Jun; 117(6):910-918. PubMed ID: 36867356 [TBL] [Abstract][Full Text] [Related]
4. Clonality profile in relapsed precursor-B-ALL children by GeneScan and sequencing analyses. Consequences on minimal residual disease monitoring. Germano G; del Giudice L; Palatron S; Giarin E; Cazzaniga G; Biondi A; Basso G Leukemia; 2003 Aug; 17(8):1573-82. PubMed ID: 12886245 [TBL] [Abstract][Full Text] [Related]
5. Measurable residual disease analysis in paediatric acute lymphoblastic leukaemia patients with ABL-class fusions. Venn NC; Huang L; Hovorková L; Muskovic W; Wong M; Law T; Heatley SL; Khaw SL; Revesz T; Dalla Pozza L; Shaw PJ; Fraser C; Moore AS; Cross S; Bendak K; Norris MD; Henderson MJ; White DL; Cowley MJ; Trahair TN; Zuna J; Sutton R Br J Cancer; 2022 Sep; 127(5):908-915. PubMed ID: 35650277 [TBL] [Abstract][Full Text] [Related]
6. Highly personalized detection of minimal Ewing sarcoma disease burden from plasma tumor DNA. Hayashi M; Chu D; Meyer CF; Llosa NJ; McCarty G; Morris CD; Levin AS; Wolinsky JP; Albert CM; Steppan DA; Park BH; Loeb DM Cancer; 2016 Oct; 122(19):3015-23. PubMed ID: 27351911 [TBL] [Abstract][Full Text] [Related]
7. Whole-genome sequencing identifies patient-specific DNA minimal residual disease markers in neuroblastoma. van Wezel EM; Zwijnenburg D; Zappeij-Kannegieter L; Bus E; van Noesel MM; Molenaar JJ; Versteeg R; Fiocco M; Caron HN; van der Schoot CE; Koster J; Tytgat GA J Mol Diagn; 2015 Jan; 17(1):43-52. PubMed ID: 25445214 [TBL] [Abstract][Full Text] [Related]
8. Analysis of minimal residual disease by Ig/TCR gene rearrangements: guidelines for interpretation of real-time quantitative PCR data. van der Velden VH; Cazzaniga G; Schrauder A; Hancock J; Bader P; Panzer-Grumayer ER; Flohr T; Sutton R; Cave H; Madsen HO; Cayuela JM; Trka J; Eckert C; Foroni L; Zur Stadt U; Beldjord K; Raff T; van der Schoot CE; van Dongen JJ; Leukemia; 2007 Apr; 21(4):604-11. PubMed ID: 17287850 [TBL] [Abstract][Full Text] [Related]
9. Flow cytometry and IG/TCR quantitative PCR for minimal residual disease quantitation in acute lymphoblastic leukemia: a French multicenter prospective study on behalf of the FRALLE, EORTC and GRAALL. Garand R; Beldjord K; Cavé H; Fossat C; Arnoux I; Asnafi V; Bertrand Y; Boulland ML; Brouzes C; Clappier E; Delabesse E; Fest T; Garnache-Ottou F; Huguet F; Jacob MC; Kuhlein E; Marty-Grès S; Plesa A; Robillard N; Roussel M; Tkaczuk J; Dombret H; Macintyre E; Ifrah N; Béné MC; Baruchel A Leukemia; 2013 Feb; 27(2):370-6. PubMed ID: 23070018 [TBL] [Abstract][Full Text] [Related]
10. Circulating Plasma Tumor DNA Is Superior to Plasma Tumor RNA Detection in Ewing Sarcoma Patients: ptDNA and ptRNA in Ewing Sarcoma. Bodlak A; Chang K; Channel J; Treece AL; Donaldson N; Cost CR; Garrington TP; Greffe B; Luna-Fineman S; Sopfe J; Loeb DM; Hayashi M J Mol Diagn; 2021 Jul; 23(7):872-881. PubMed ID: 33887462 [TBL] [Abstract][Full Text] [Related]
11. Predictive value of minimal residual disease in Philadelphia-chromosome-positive acute lymphoblastic leukemia treated with imatinib in the European intergroup study of post-induction treatment of Philadelphia-chromosome-positive acute lymphoblastic leukemia, based on immunoglobulin/T-cell receptor and BCR/ABL1 methodologies. Cazzaniga G; De Lorenzo P; Alten J; Röttgers S; Hancock J; Saha V; Castor A; Madsen HO; Gandemer V; Cavé H; Leoni V; Köhler R; Ferrari GM; Bleckmann K; Pieters R; van der Velden V; Stary J; Zuna J; Escherich G; Stadt UZ; Aricò M; Conter V; Schrappe M; Valsecchi MG; Biondi A Haematologica; 2018 Jan; 103(1):107-115. PubMed ID: 29079599 [TBL] [Abstract][Full Text] [Related]
12. Ewing family tumors: potential prognostic value of reverse-transcriptase polymerase chain reaction detection of minimal residual disease in peripheral blood samples. de Alava E; Lozano MD; Patiño A; Sierrasesúmaga L; Pardo-Mindán FJ Diagn Mol Pathol; 1998 Jun; 7(3):152-7. PubMed ID: 9836070 [TBL] [Abstract][Full Text] [Related]
13. An update on PCR use for minimal residual disease monitoring in acute lymphoblastic leukemia. Nunes V; Cazzaniga G; Biondi A Expert Rev Mol Diagn; 2017 Nov; 17(11):953-963. PubMed ID: 28891364 [TBL] [Abstract][Full Text] [Related]
14. [Identification of immunoglobulin and T-cell receptor gene rearrangements--prerequisite for monitoring of minimal residual disease in Polish acute lymphoblastic leukemia patients based on European standards. Preliminary results]. Dawidowska M; Derwich K; Szczepański T; Jółkowska J; Witt M; Wachowiak J Med Wieku Rozwoj; 2006; 10(1 Pt 2):323-34. PubMed ID: 17028396 [TBL] [Abstract][Full Text] [Related]
15. High sensitivity and clonal stability of the genomic fusion as single marker for response monitoring in ETV6-RUNX1-positive acute lymphoblastic leukemia. Hoffmann J; Krumbholz M; Gutiérrez HP; Fillies M; Szymansky A; Bleckmann K; Zur Stadt U; Köhler R; Kuiper RP; Horstmann M; von Stackelberg A; Eckert C; Metzler M Pediatr Blood Cancer; 2019 Aug; 66(8):e27780. PubMed ID: 31034759 [TBL] [Abstract][Full Text] [Related]
16. Concurrent detection of minimal residual disease (MRD) in childhood acute lymphoblastic leukaemia by flow cytometry and real-time PCR. Kerst G; Kreyenberg H; Roth C; Well C; Dietz K; Coustan-Smith E; Campana D; Koscielniak E; Niemeyer C; Schlegel PG; Müller I; Niethammer D; Bader P Br J Haematol; 2005 Mar; 128(6):774-82. PubMed ID: 15755280 [TBL] [Abstract][Full Text] [Related]
17. Minimal residual disease detection using real-time quantitative PCR analysis of immunoglobulin and T-cell receptor gene rearrangements in the non-MRD-based ALL IC-BFM 2002 protocol for childhood ALL: Slovak experience. Kolenova A; Hikkel I; Ilencikova D; Hikkelova M; Sejnova D; Kaiserova E; Cizmar A; Puskacova J; Bubanska E; Oravkinova I; Gencik M Neoplasma; 2010; 57(6):552-61. PubMed ID: 20845994 [TBL] [Abstract][Full Text] [Related]
18. Real-time quantitative PCR for the detection of minimal residual disease in acute lymphoblastic leukemia using junctional region specific TaqMan probes. Pongers-Willemse MJ; Verhagen OJ; Tibbe GJ; Wijkhuijs AJ; de Haas V; Roovers E; van der Schoot CE; van Dongen JJ Leukemia; 1998 Dec; 12(12):2006-14. PubMed ID: 9844931 [TBL] [Abstract][Full Text] [Related]
19. MRD detection in acute lymphoblastic leukemia patients using Ig/TCR gene rearrangements as targets for real-time quantitative PCR. van der Velden VH; van Dongen JJ Methods Mol Biol; 2009; 538():115-50. PubMed ID: 19277574 [TBL] [Abstract][Full Text] [Related]